Skip to main content
Caplight Logo









Cancentus

Cancentus

Private
AllschwilHealthcare & Life Scienceshttps://cancentus.com/

Last Round

Accelerator

Apr 14, 2026

Total Funding Raised

$560,000

Company Overview

Cancentus is a biotechnology company that develops selective cancer therapies by exploiting oncogene-induced DNA replication stress, a key vulnerability unique to cancer cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

precision oncologyAI drug discoveryantibody-drug conjugateADChelicase inhibitorsDNA replication stresstargeted cancer therapyADC payloadscancer therapeuticsAI-driven drug discoveryAIDDin-silico drug discoverydrug discovery servicescombination therapieshit identificationlead optimizationbiotech partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cancentus Comparables

Compare Cancentus with similar companies based on industry and business-model similarity.

Cancentus comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
FoRx Therapeutics
78%
Artios Pharma
76%
Rakovina Therapeutics Inc.
76%

Cancentus Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorApr 14, 2026

Cancentus Investors

Notable investors and investment history

Cancentus investors
InvestorRounds
InnosuisseAccelerator
BaseLaunchAccelerator

Cancentus Filings

Explore SEC and related filing metadata, where available.

Cancentus filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cancentus's valuation, stock price, and market status.

Is Cancentus a public or private company?

Cancentus is a private company.

What is the current stock price of Cancentus?

Cancentus is a private company with no public stock price. No recent secondary market data is available.

How much is Cancentus worth (valuation)?

Valuation information for Cancentus is not publicly available.

Can I buy Cancentus stock?

Cancentus shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cancentus's last funding round?

Funding round information for Cancentus is not publicly available.

Who are the main investors in Cancentus?

Investor information for Cancentus is not publicly disclosed.

Will Cancentus IPO soon?

No public IPO plans have been announced for Cancentus.

How can I track Cancentus secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cancentus's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAllschwil
Employee Range3
Year Founded2026
Last FundingApr 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?